微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 57.94% | 0.46% | -3.12% | 57/158 | 22.23% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 59.8% | 3.11% | 2.61% | 52/158 | 32.75% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 58.29% | -1.03% | 5.88% | 54/158 | 51.26% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 55.05% | 6.89% | -4.55% | 68/158 | 51.17% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 57.67% | 13.86% | -0.57% | 62/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 58% | 13.48% | -1.51% | 58/158 | 38.03% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 58.89% | 5.84% | 14.35% | 56/158 | 52.88% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 51.5% | -6% | 1.67% | 83/158 | 53.39% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 50.65% | -7.31% | -0.9% | 77/158 | 6.36% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 51.11% | -11.48% | -8.14% | 81/158 | 21.22% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 55.64% | 0.41% | 1.55% | 69/158 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 54.79% | -2.92% | 0.25% | 76/158 | 54.96% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 54.65% | -2.83% | -5.35% | 66/158 | 46.94% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 57.74% | 2.99% | 4.2% | 66/158 | 47.38% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 55.41% | 2.48% | -1.81% | 63/158 | 54.17% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 56.43% | 8.98% | 0.34% | 65/158 | -145.98% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 56.24% | 6.87% | 0.31% | 60/158 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 56.06% | 9.3% | 3.69% | 59/158 | 54.3% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 54.07% | 9.62% | 4.42% | 56/158 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 51.78% | 15.97% | -1.61% | 71/158 | -1213.5% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 52.63% | 19.85% | 2.6% | 57/158 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 51.29% | 16.47% | 4% | 63/158 | 55.32% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 49.32% | 10.26% | 10.46% | 57/158 | 51.34% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 44.65% | -26.07% | 1.68% | 83/158 | -207.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 43.91% | -27.58% | -0.29% | 64/158 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 44.04% | -30.4% | -1.55% | 65/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 44.73% | -22.59% | -25.94% | 63/158 | 54.06% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 60.4% | 9.11% | -0.38% | 41/158 | 52.5% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 60.63% | 2% | -4.18% | 30/158 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 63.28% | 2% | 9.51% | 27/158 | 47.95% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 57.78% | 14.08% | 4.37% | 28/158 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 55.36% | 7.26% | 7.26% | 39/158 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2015-12-31 | 51.61% | -4.38% | 1.9% | 39/158 | 46.24% | 贝达药业 | 95.89% | 行业排名> |
| 2015-03-31 | 50.65% | 2% | -6.16% | 28/158 | 43.46% | 微芯生物 | 97.46% | 行业排名> |
| 2014-12-31 | 53.98% | 16.22% | 16.22% | 34/158 | 43.42% | 贝达药业 | 97.01% | 行业排名> |